Eris Lifesciences Limited. Q4 results show revenue fell from 425.49 to 403.80 crores, a 5.10% decrease in growth. EPS also dropped from ₹7.49 to ₹4.79, down by 36.05%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Eris Lifesciences Ltd. shared its Q4 results on Wednesday. They earned 403.80 crores in revenue this quarter, but that’s less than the 425.49 crores they made last quarter. Unfortunately, the company’s growth decreased by 5.10 percent when comparing the two quarters.
In terms of profits, Eris Lifesciences Ltd’s PAT (Profit After Tax) for this quarter was 65.41 crores, down from 101.85 crores in the previous quarter. Their quarter-to-quarter growth declined by 35.78 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹4.79, which is a decrease of 36.05% from the ₹7.49 EPS in the previous quarter.
Also read: ☞ ” Jindal Stainless Q4FY23 Results: Consolidated PAT Rise to Rs 765.79 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 1696.302 crores this year (2023), which is 23.53 percent higher than last year’s total revenue of 1373.137 crores.
This year’s PAT (Profit After Tax) is 382.15 crores, which is also 5.90% lower than last year’s PAT of 406.11 crores.
The EPS (Earnings Per Share) for this year is ₹28.07, which is 6.06% less than the EPS of ₹29.88 earned last year.
Eris Lifesciences Share Dividend Announcement / Record Date:
The record date for the dividend has not arrived yet.
About Eris Lifesciences:
Eris Lifesciences Ltd stands out as the sole publicly traded Indian pharmaceutical company focused exclusively on domestic branded formulations. With an impressive ranking of #21 in the IPM (Indian Pharmaceutical Market), Eris has swiftly emerged as a dominant player in the cardio-metabolic sector since its establishment a mere 15 years ago.
Download Full PDF Q4 Results of Eris Lifesciences: Click Here
For more of the Latest News, Click Here
One thought on “Eris Lifesciences Q4FY23 Results: Consolidated PAT Drop to Rs 65.41 Cr”